The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Prostate cancers along with several malignant gliomas, gastric and pancreatic cancers showed strong cytoplasmic positivity. Several colorectal, breast, urothelial, gastric, pancreatic and liver cancers were moderately stained. Remaining malignant cells were weakly stained or negative.
A majority of colorectal, breast, testicular and thyroid cancers as well as several ovarian cancers and malignant melanomas displayed moderate cytoplasmic staining. Remaining malignancies were in general weakly stained or negative.
Moderate cytoplasmic positivity was observed in most malignancies.
Hepatocellular carcinomas were strongly stained. Several renal cancers, malignant lymphomas, melanomas and gliomas were weakly stained.
Colorectal cancer and a few cases of breast, renal, pancreatic and liver cancers showed moderate cytoplasmic positivity. Remaining malignancies were weakly stained or negative.
Validation
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
